02552

2.0150.98%
CL

Changhong Li

Chief Scientific Officer

Dr. Changhong Li Ph.D., serves as Chief Scientific Officer at Hua Medicine (Shanghai) Ltd. since December 1, 2022 and serves as Chief Executive Officer of Nanjing AscendRare Pharmaceutical Technology Co., Ltd. - a wholly owned subsidiary of Hua Medicine since December 1, 2022. He has experience in the fields of islet biology, metabolism and translational medical research. In Oct. 2018,he founded Nanjing AscendRare Pharmaceutical Technology Co., Ltd. and held the position of General Manager until Nov. 2022. From 2000 to 2018, he worked at the Children's Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania in the United States for over years, including sylvania and the Children's Hospital of Philadelphia. He was trained by and has collaborated closely with the renowned pediatric endocrinologist Dr. Charles Stanley and the preeminent biochemist. He has published more than 60 SCI articles in internationally renowned academic journals such as JBC, Diabetes, JCI and Cell Metabolism. He has also published more than 10 Chinese articles in several core Chinese medical journals such as Chinese Medical Journal and Chinese Journal of Internal Medicine. He obtained his bachelor degree of medicine from Chengde Medical College in 1989 and his M.D and Ph.D from Beijing Medical University (now known as Peking University School of Medicine) in 1996.

Positions